Jackson Square Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Jackson Square Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-527	Closed	-$407K	–	152
2026 Q1	$407K	Hold	527	–	–	0.09%	103
2025 Q4	$407K	Buy	+527	New	+$358K	0.08%	118
2020 Q4	–	Sell	-23	Closed	-$13K	–	291
2020 Q3	$13K	Hold	23	–	–	0.01%	252
2020 Q2	$14K	Sell	23 -2	-8%	-$1.14K	0.01%	226
2020 Q1	$12K	Buy	25 +2	+9%	+$825	0.01%	207
2019 Q4	$9K	Buy	+23	New	+$7.74K	0.01%	268

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Jackson Square Capital's REGN Position: Q2 2026 in Review

Jackson Square Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 527 shares — an estimated $407K sold.

Jackson Square Capital first reported a position in REGN in Q4 2019 and held it in 6 quarters. The position peaked at $407K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Jackson Square Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jackson Square Capital sold 527 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $407K.
Jackson Square Capital first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 6 quarters.
Jackson Square Capital's Regeneron Pharmaceuticals position peaked at $407K in Q1 2026.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Jackson Square Capital's 13F filing for Q2 2026, filed 21 Jul 2026.